The United Kingdom and the United States have forged a significant commercial pact that will maintain zero duties on UK pharmaceutical shipments going into the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has agreed to boost expenditure on pharmaceuticals through the public health system. This move secures that tariffs on these key goods will be held at nothing for a period of three years.
This agreement is in response to earlier warnings to significantly raise import taxes on patented pharmaceutical products, with potential rates floated reaching 100%.
"This arrangement between the United Kingdom strengthens the worldwide climate for new treatments and brings much-needed fairness to transatlantic pharmaceutical trade," a statement said.
Commercial Impact
Pharmaceuticals constitute one of the the United Kingdom's largest export categories to the United States, which is by far the largest market for major British pharmaceutical firms.
Export figures reveal that in the year leading up to the third quarter, the UK exported pharmaceutical products worth over eleven billion pounds to the US. This value accounted for 17.4% of all goods exports in that span.
"This agreement protects work, increases capital expenditure and sets the stage for the UK to emerge as a global hub for medical research," the Business and Trade Secretary commented.
Detailed UK Commitments
The pact includes several notable changes from the UK:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it deems new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a aim to raise total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to stay within budget will be limited at 15%. Previously, repayments exceeded twenty percent.
Broader Context
This agreement comes amid a protracted dispute between the pharmaceutical industry and the ministers over drug pricing and approval rates.
The disagreement were exacerbated by claims that American consumers were charged several times more for the identical medicines than patients in the Britain and the EU.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or scrapped, while major funding commitments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS had to increase expenditure on treatments, noting that its expenditure on drugs had declined as a percentage of its total funding over the previous ten-year period.
